Soluble Aβ aggregates can inhibit prion propagation

DSpace/Manakin Repository

Soluble Aβ aggregates can inhibit prion propagation

Citable link to this page


Title: Soluble Aβ aggregates can inhibit prion propagation
Author: Sarell, Claire J.; Quarterman, Emma; Yip, Daniel C.-M.; Terry, Cassandra; Nicoll, Andrew J.; Wadsworth, Jonathan D. F.; Farrow, Mark A.; Walsh, Dominic M.; Collinge, John

Note: Order does not necessarily reflect citation order of authors.

Citation: Sarell, Claire J., Emma Quarterman, Daniel C.-M. Yip, Cassandra Terry, Andrew J. Nicoll, Jonathan D. F. Wadsworth, Mark A. Farrow, Dominic M. Walsh, and John Collinge. 2017. “Soluble Aβ aggregates can inhibit prion propagation.” Open Biology 7 (11): 170158. doi:10.1098/rsob.170158.
Full Text & Related Files:
Abstract: Mammalian prions cause lethal neurodegenerative diseases such as Creutzfeldt–Jakob disease (CJD) and consist of multi-chain assemblies of misfolded cellular prion protein (PrPC). Ligands that bind to PrPC can inhibit prion propagation and neurotoxicity. Extensive prior work established that certain soluble assemblies of the Alzheimer's disease (AD)-associated amyloid β-protein (Aβ) can tightly bind to PrPC, and that this interaction may be relevant to their toxicity in AD. Here, we investigated whether such soluble Aβ assemblies might, conversely, have an inhibitory effect on prion propagation. Using cellular models of prion infection and propagation and distinct Aβ preparations, we found that the form of Aβ assemblies which most avidly bound to PrP in vitro also inhibited prion infection and propagation. By contrast, forms of Aβ which exhibit little or no binding to PrP were unable to attenuate prion propagation. These data suggest that soluble aggregates of Aβ can compete with prions for binding to PrPC and emphasize the bidirectional nature of the interplay between Aβ and PrPC in Alzheimer's and prion diseases. Such inhibitory effects of Aβ on prion propagation may contribute to the apparent fall-off in the incidence of sporadic CJD at advanced age where cerebral Aβ deposition is common.
Published Version: doi:10.1098/rsob.170158
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search